- Home
- IONS vs SNDR Comparison
IONS vs SNDR Comparison
Compare IONS & SNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- SNDR
- Stock Information
- Founded
- IONS 1989
- SNDR 1935
- Country
- IONS United States
- SNDR United States
- Employees
- IONS N/A
- SNDR N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- SNDR Trucking Freight/Courier Services
- Sector
- IONS Health Care
- SNDR Industrials
- Exchange
- IONS Nasdaq
- SNDR Nasdaq
- Market Cap
- IONS 6.0B
- SNDR 5.2B
- IPO Year
- IONS 1991
- SNDR 2017
- Fundamental
- Price
- IONS $31.43
- SNDR $29.75
- Analyst Decision
- IONS Buy
- SNDR Buy
- Analyst Count
- IONS 18
- SNDR 14
- Target Price
- IONS $62.00
- SNDR $29.08
- AVG Volume (30 Days)
- IONS 1.5M
- SNDR 783.5K
- Earning Date
- IONS 02-19-2025
- SNDR 01-30-2025
- Dividend Yield
- IONS N/A
- SNDR 1.28%
- EPS Growth
- IONS N/A
- SNDR N/A
- EPS
- IONS N/A
- SNDR 0.64
- Revenue
- IONS $803,067,000.00
- SNDR $5,323,100,000.00
- Revenue This Year
- IONS N/A
- SNDR N/A
- Revenue Next Year
- IONS $10.85
- SNDR $8.29
- P/E Ratio
- IONS N/A
- SNDR $46.71
- Revenue Growth
- IONS 30.57
- SNDR N/A
- 52 Week Low
- IONS $31.41
- SNDR $20.50
- 52 Week High
- IONS $52.49
- SNDR $33.90
- Technical
- Relative Strength Index (RSI)
- IONS 33.19
- SNDR 48.99
- Support Level
- IONS $32.61
- SNDR $28.06
- Resistance Level
- IONS $35.37
- SNDR $30.80
- Average True Range (ATR)
- IONS 1.28
- SNDR 0.64
- MACD
- IONS -0.30
- SNDR 0.14
- Stochastic Oscillator
- IONS 0.36
- SNDR 61.68
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.